Preventing CMV after a haploidentical stem cell transplant
Part of Immune system & allergy, Infections clinical trials.
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult who had a haploidentical (half-matched) stem cell transplant from a donor
- The donor must test positive for CMV, and the donor must not have an active infection around the cell collection time
- Your blood counts must be starting to recover after transplant (neutrophils above a certain level for at least 3 check times)
- You cannot be on steroid medicines at the time of the planned cell infusion (for example, about 0.5 mg/kg/day prednisone or equivalent)
- You must not have serious ongoing illness issues: very poor activity level, severe organ side effects, uncontrolled or unresolved infection, or persistent fevers just before infusion
- You must not have moderate-to-severe graft-versus-host disease (GVHD), a relapse before infusion, or a new CMV infection/reactivation before infusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This study checks whether certain virus levels in your blood after a stem cell transplant can help predict or prevent CMV infection. It aims to improve how doctors monitor and protect patients from this virus.
This trial is testing whether giving special immune cells from a family donor (called CTLs) along with regular antiviral medicine is better than regular medicine alone for people who have a stubborn adenovirus or cytomegalovirus infection after a stem cell transplant.
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Hear when a new CMV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.